Literature DB >> 17556658

Dilated cardiomyopathy mutant tropomyosin mice develop cardiac dysfunction with significantly decreased fractional shortening and myofilament calcium sensitivity.

Sudarsan Rajan1, Rafeeq P H Ahmed, Ganapathy Jagatheesan, Natalia Petrashevskaya, Greg P Boivin, Dalia Urboniene, Grace M Arteaga, Beata M Wolska, R John Solaro, Stephen B Liggett, David F Wieczorek.   

Abstract

Mutations in striated muscle alpha-tropomyosin (alpha-TM), an essential thin filament protein, cause both dilated cardiomyopathy (DCM) and familial hypertrophic cardiomyopathy. Two distinct point mutations within alpha-tropomyosin are associated with the development of DCM in humans: Glu40Lys and Glu54Lys. To investigate the functional consequences of alpha-TM mutations associated with DCM, we generated transgenic mice that express mutant alpha-TM (Glu54Lys) in the adult heart. Results showed that an increase in transgenic protein expression led to a reciprocal decrease in endogenous alpha-TM levels, with total myofilament TM protein levels remaining unaltered. Histological and morphological analyses revealed development of DCM with progression to heart failure and frequently death by 6 months. Echocardiographic analyses confirmed the dilated phenotype of the heart with a significant decrease in the left ventricular fractional shortening. Work-performing heart analyses showed significantly impaired systolic, and diastolic functions and the force measurements of cardiac myofibers revealed that the myofilaments had significantly decreased Ca(2+) sensitivity and tension generation. Real-time RT-PCR quantification demonstrated an increased expression of beta-myosin heavy chain, brain natriuretic peptide, and skeletal actin and a decreased expression of the Ca(2+) handling proteins sarcoplasmic reticulum Ca(2+)-ATPase and ryanodine receptor. Furthermore, our study also indicates that the alpha-TM54 mutation decreases tropomyosin flexibility, which may influence actin binding and myofilament Ca(2+) sensitivity. The pathological and physiological phenotypes exhibited by these mice are consistent with those seen in human DCM and heart failure. As such, this is the first mouse model in which a mutation in a sarcomeric thin filament protein, specifically TM, leads to DCM.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17556658     DOI: 10.1161/CIRCRESAHA.107.148379

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  47 in total

1.  Tropomyosin isoforms and reagents.

Authors:  Galina Schevzov; Shane P Whittaker; Thomas Fath; Jim Jc Lin; Peter W Gunning
Journal:  Bioarchitecture       Date:  2011-07-01

2.  Use of 2-D DIGE analysis reveals altered phosphorylation in a tropomyosin mutant (Glu54Lys) linked to dilated cardiomyopathy.

Authors:  Chad M Warren; Grace M Arteaga; Sudarsan Rajan; Rafeeq P H Ahmed; David F Wieczorek; R John Solaro
Journal:  Proteomics       Date:  2008-01       Impact factor: 3.984

3.  Functional effects of a tropomyosin mutation linked to FHC contribute to maladaptation during acidosis.

Authors:  Katherine A Sheehan; Grace M Arteaga; Aaron C Hinken; Fernando A Dias; Cibele Ribeiro; David F Wieczorek; R John Solaro; Beata M Wolska
Journal:  J Mol Cell Cardiol       Date:  2010-11-01       Impact factor: 5.000

4.  Cardiac myosin light chain phosphorylation and inotropic effects of a biased ligand, TRV120023, in a dilated cardiomyopathy model.

Authors:  Madhusudhan Tarigopula; Robert T Davis; Paul T Mungai; David M Ryba; David F Wieczorek; Conrad L Cowan; Jonathan D Violin; Beata M Wolska; R John Solaro
Journal:  Cardiovasc Res       Date:  2015-06-04       Impact factor: 10.787

5.  Tropomyosin pseudo-phosphorylation results in dilated cardiomyopathy.

Authors:  Sudarsan Rajan; Ganapathy Jagatheesan; Natalia Petrashevskaya; Brandon J Biesiadecki; Chad M Warren; Tara Riddle; Stephen Liggett; Beata M Wolska; R John Solaro; David F Wieczorek
Journal:  J Biol Chem       Date:  2018-12-19       Impact factor: 5.157

6.  Expression of tropomyosin-κ induces dilated cardiomyopathy and depresses cardiac myofilament tension by mechanisms involving cross-bridge dependent activation and altered tropomyosin phosphorylation.

Authors:  Chehade N Karam; Chad M Warren; Sudarsan Rajan; Pieter P de Tombe; David F Wieczorek; R John Solaro
Journal:  J Muscle Res Cell Motil       Date:  2011-01-09       Impact factor: 2.698

7.  Phenotypic heterogeneity of sarcomeric gene mutations: a matter of gain and loss?

Authors:  Luisa Mestroni
Journal:  J Am Coll Cardiol       Date:  2009-07-21       Impact factor: 24.094

8.  A myosin activator improves actin assembly and sarcomere function of human-induced pluripotent stem cell-derived cardiomyocytes with a troponin T point mutation.

Authors:  K M Broughton; J Li; E Sarmah; C M Warren; Y-H Lin; M P Henze; V Sanchez-Freire; R J Solaro; B Russell
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-05-06       Impact factor: 4.733

Review 9.  Investigations into tropomyosin function using mouse models.

Authors:  Ganapathy Jagatheesan; Sudarsan Rajan; David F Wieczorek
Journal:  J Mol Cell Cardiol       Date:  2009-10-14       Impact factor: 5.000

10.  Challenging current paradigms related to cardiomyopathies. Are changes in the Ca2+ sensitivity of myofilaments containing cardiac troponin C mutations (G159D and L29Q) good predictors of the phenotypic outcomes?

Authors:  David Dweck; Nir Hus; James D Potter
Journal:  J Biol Chem       Date:  2008-09-26       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.